Covid-19 | Page 55 of 100 | Links Medicus Content Curation & Alerts in Medicine

COVID-19 long haulers – “With the risks of drug development prohibitive, repurposed or repositioned medicines appear the best hope against long-COVID, a condition that still raises many unanswered questions”.

17 Aug, 2021 | 08:57h | UTC

COVID-19 long haulers – Nature Biotechnology

Related: M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Commentary on Twitter

A News Feature published in @NatureBiotech reports on how repurposed or repositioned medicines appear to be the best hope against long-COVID. https://t.co/Hc9s2tr8N8 pic.twitter.com/ue2sH4gWzT

— Nature Portfolio (@NaturePortfolio) August 16, 2021

FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.

16 Aug, 2021 | 01:22h | UTC

Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals – U.S. Food & Drug Administration

Commentaries:

Statement on FDA Authorization of Supplemental Vaccine Dose for Immunocompromised Patients – Infectious Diseases Society of America

CDC, FDA recommend COVID booster for immune-compromised – CIDRAP

FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised – STAT

The fine print: Understanding the new policy authorizing extra Covid vaccine doses for the immunocompromised – STAT

Covid booster: US approves third jab for the immunocompromised – BBC

CDC Committee Approves Third Covid-19 Shot For Immunocompromised People—Here’s Who Should Get One – Forbes

CDC Panel Recommends 3rd Vaccine Dose For Immunocompromised People – NPR

6 Things To Know If You’re Immunocompromised And Considering A 3rd Shot – NPR

CDC recommends third Covid-19 vaccine dose for certain immunocompromised people – CNN

Commentary on Twitter

The Infectious Diseases Society of America (IDSA) supports the @FDA and @CDCgov's decision to authorize a supplemental vaccine dose for immunocompromised patients.

Read our statement: https://t.co/odzzSgIxnY pic.twitter.com/4PZfUwpjhM

— IDSA (@IDSAInfo) August 13, 2021

Perspective | Don’t panic, but breakthrough cases may be a bigger problem than you’ve been told.

16 Aug, 2021 | 01:17h | UTC

Don’t Panic, But Breakthrough Cases May Be a Bigger Problem Than You’ve Been Told – Intelligencer

Commentary on Twitter (thread – click for more)

The vaccines are still performing quite well in preventing severe disease. But with Delta they are doing much worse in stopping transmission. Breakthroughs are probably now 10-20% of new infections, and perhaps as much as 5% of new deaths. A thread. (1/x) https://t.co/NvGends1ZP

— David Wallace-Wells (@dwallacewells) August 12, 2021

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

16 Aug, 2021 | 01:19h | UTC

COVID-19 Vaccines While Pregnant or Breastfeeding – Centers for Disease Control and Prevention

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Opinion | Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective.

[Preprint] Impact of the COVID-19 pandemic on early child cognitive development: initial findings in a longitudinal observational study of child health.

16 Aug, 2021 | 01:11h | UTC

Impact of the COVID-19 Pandemic on Early Child Cognitive Development: Initial Findings in a Longitudinal Observational Study of Child Health – medRxiv

Commentary: Children born during pandemic have lower IQs, US study finds – Researchers blame lack of stimulation as parents balanced childcare with working from home – The Guardian

Commentary on Twitter (thread – click for more)

Preprint on the development of children born before and during the pandemic in the US.

"We find that children born during the pandemic have significantly reduced verbal, motor, and overall cognitive performance compared to children born pre-pandemic."
1/https://t.co/NInexSUDAi

— Prof Francois Balloux (@BallouxFrancois) August 15, 2021

Antibody responses after a single dose of AstraZeneca Covid-19 vaccine in previously infected individuals were similar or higher compared to antibody responses in SARS-CoV-2 naïve participants who received two doses of Pfizer mRNA vaccine.

16 Aug, 2021 | 01:15h | UTC

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 – EBioMedicine

Commentary (on the preprint): Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study – News Medical

Durability of Moderna vaccine–induced antibodies against SARS-CoV-2 variants.

16 Aug, 2021 | 01:13h | UTC

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants – Science

Commentary:

Moderna COVID-19 vaccine found to be still effective after six months – MedicalXpress

Moderna’s Covid-19 vaccine protects against Delta variant, study finds – CNN

Expert reaction to study looking at the Moderna COVID-19 vaccine and antibody response to variants of concern – Science Media Centre

Commentary on Twitter

The majority of individuals who received both doses of the mRNA-1273 (Moderna) vaccine maintained binding and functional antibodies against #SARSCoV2 variants for six months, a new Science study shows. https://t.co/jf98Rgasop pic.twitter.com/IN1cP33zxN

— Science Magazine (@ScienceMagazine) August 12, 2021

Bioethics | Should we tell stories of vaccine sceptics who have died of COVID?

16 Aug, 2021 | 01:06h | UTC

Should we tell stories of vaccine sceptics who have died of COVID? – The Conversation

Opinion: “fear of covid-19 in kids is getting ahead of the data”.

16 Aug, 2021 | 01:09h | UTC

Fear of COVID-19 in Kids Is Getting Ahead of the Data – The Atlantic

Study suggests a potential protective benefit from MMR and TDP vaccines in reducing the risk of severe Covid-19 infections.

16 Aug, 2021 | 01:04h | UTC

Protective heterologous T cell immunity in COVID-19 induced by the trivalent Measles-Mumps-Rubella and Tetanus-Diptheria-Pertussis vaccine antigens – Med

Commentary on Twitter

New @MedCellPress
Prior Measles-Mumps-Rubella (MMR) or Tetanus-Diptheria-Pertussis (Tdap) vaccination induces a T-cell response that overlaps with #SARSCoV2 and appears to offer some (~20-30%) protection from severe Covid-19https://t.co/fYT7Qole8s pic.twitter.com/hMkHXvNQYU

— Eric Topol (@EricTopol) August 14, 2021

Perspective: How the pandemic now ends.

13 Aug, 2021 | 10:03h | UTC

How the pandemic now ends – The Atlantic

Commentary on Twitter (thread – click for more)

🚨I wrote a big piece about how Delta affects the pandemic endgame.

Many folks are upset & confused by the last month. Here's an attempt to reset expectations, lay out our goals, map the near-term future, & show how the pandemic ends–which it will. 1/https://t.co/4Ukv7zs91X

— Ed Yong is not here (@edyong209) August 12, 2021

How do vaccinated people spread Delta? What the science says.

13 Aug, 2021 | 09:55h | UTC

How do vaccinated people spread Delta? What the science says – Nature

Opinion: Making vaccines available to other countries before offering domestic booster vaccinations.

13 Aug, 2021 | 09:48h | UTC

Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations – JAMA

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

13 Aug, 2021 | 09:58h | UTC

Could This Be Our First Effective, Inexpensive, Widely Available Outpatient Treatment for COVID-19? – HIV and ID Observations

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

13 Aug, 2021 | 10:01h | UTC

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison – American Family Physician

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Opinion: Time for a smart approach to boosters.

13 Aug, 2021 | 09:51h | UTC

Time for a Smart Approach to Boosters – Think Global Health

Antibody response to COVID-19 vaccination in adults with hematologic malignant disease.

13 Aug, 2021 | 09:47h | UTC

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease – JAMA Oncology

Commentary on Twitter

Honored Jama Onc has published our work. Please get yourself vaccinated for those in whom it does not work. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease https://t.co/BXkUQGMmbO via @JAMAOnc part of @JAMANetwork

— Tom Ollila (@OllilaTom) August 11, 2021

How COVID-19 will change the management of other respiratory viral infections.

13 Aug, 2021 | 09:52h | UTC

How COVID-19 will change the management of other respiratory viral infections – Intensive Care Medicine

Commentary on Twitter

Still in the midst of #SARSCoV2 #pandemic, still so much to learn… but #COVID19 experience should transform approach to research on RVIs
🦠antiviral therapy
🦠corticosteroids
🦠specific immune modulation
🦠anticoagulation
🦠respiratory support#COVIDFOAM https://t.co/WVKRSJARvl pic.twitter.com/qMkB4tkz06

— Intensive Care Medicine (@yourICM) August 11, 2021

RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.

12 Aug, 2021 | 09:56h | UTC

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients – New England Journal of Medicine

Editorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

[Preprint] 3rd AstraZeneca shot gives strong immunity.

Commentaries on Twitter

https://twitter.com/hildabast/status/1425576801850433537

The authors conclude that a third-dose booster of mRNA-1273 vaccine should be considered for transplant recipients. https://t.co/Q3gakSaNjd pic.twitter.com/CMN8f7cq29

— NEJM (@NEJM) August 11, 2021

RCT: Evaluation of Moderna mRNA vaccine in adolescents.

12 Aug, 2021 | 09:58h | UTC

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

Commentaries on Twitter

The mRNA-1273 vaccine was effective in preventing #COVID19 in 12-to-17-year-olds. Immune response was similar to young adults. https://t.co/aC3Dmjqe2T pic.twitter.com/9RxgHApW29

— NEJM (@NEJM) August 11, 2021

The @moderna_tx covid vaccine trial in 3,732 teens, placebo-controlled, published today @NEJM with both excellent safety profile and efficacy vs covid, and immune response as least as good as young adults https://t.co/PVmhjwgwsU pic.twitter.com/3uCmteaWNx

— Eric Topol (@EricTopol) August 11, 2021

Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.

12 Aug, 2021 | 09:54h | UTC

Moderna may be superior to Pfizer against delta variant — breakthrough odds rise with time – CNBC

Original Study 1 (preprint): Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence – medRxiv

Original Study 2 (preprint): Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers – medRxiv

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.

12 Aug, 2021 | 09:53h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

Commentary on Twitter

New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV
2-doses vaccine effectiveness vs infections
Pfizer 53.5%
Moderna 84.8%
Either 57.2%
(replicates gap of recent Mayo Clinic study) pic.twitter.com/ghWuWbYPLH

— Eric Topol (@EricTopol) August 11, 2021

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs.

12 Aug, 2021 | 09:02h | UTC

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs – World Health Organization

Commentary:

WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch

A giant trial of COVID-19 treatments organized by the WHO is restarting. Here are the drugs it’s betting on.

WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

Commentary on Twitter (thread – click for more)

WHO’s #COVID19 Solidarity clinical trial enters a new phase – Solidarity PLUS – with three new candidate drugs:
-artesunate
-imatinib
-infliximab

👉 https://t.co/K6tk22NnFf

— World Health Organization (WHO) (@WHO) August 11, 2021